BACKGROUND Self-report instruments for the assessment of depressive symptoms in patients with psychotic disorders are scarce. The Quick Inventory of Depressive Symptoms (QIDS-SR16) may be a useful self-report instrument, but has received little attention in this field. This paper aimed to test the psychometric properties of the QIDS-SR16 questionnaire in patients with a psychotic disorder. ME...

Introduction. Depressive symptoms are common in schizophrenia and are associated with poorer functioning, lower quality of life, and an elevated risk of suicidal behaviour. There are few studies on the occurrence and correlates of these symptoms in acutely ill patients with schizophrenia. Method. 72 acutely ill patients with schizophrenia were assessed for depression using the Calgary Depressio...

BACKGROUND Perospirone is a second-generation antipsychotic (SGA) used only in Japan, and acts as a serotonin (5-HT)1A receptor partial agonist, 5-HT2A receptor inverse agonist, and dopamine (D)₂, D₄, and α₁-adrenergic receptor antagonist. To our knowledge, no meta-analysis addressing the efficacy and effectiveness of perospirone in schizophrenia has been published to date. OBJECTIVE The aim ...

BACKGROUND Findings from previous studies linking brain-derived neurotrophic factor (BDNF) and schizophrenia are inconsistent and few studies have assessed the relationship between BDNF C270T gene polymorphisms and the clinical and cognitive symptoms of schizophrenia. AIM Compare the prevalence of the BDNF C270T gene polymorphisms between patients with schizophrenia and controls and, in the p...

Introduction Several factors related to the risk of requiring psychiatric hospitalization have been described in patients diagnosed with schizophrenia treated methods other than home treatment. With regard symptoms, high global illness severity and positive symptoms most frequently schizophrenia. However, there are no studies describing which clinical increase likelihood being hospitalized whil...

OBJECTIVE To evaluate aripiprazole once-monthly (AOM), a long-acting injectable suspension of aripiprazole, as acute treatment in patients with schizophrenia (DSM-IV-TR). METHOD Adults experiencing an acute psychotic episode were randomized to 12 weeks of double-blind treatment with AOM 400 mg or placebo (October 2012-August 2013). The primary efficacy outcome was change from baseline to endp...

OBJECTIVE Recent studies have suggested that higher insulin levels are associated with better psychopathology profiles in cross-sectional samples of patients with schizophrenia. This study examines whether drug-induced fasting insulin changes between third and eight week of treatment are related to clinical improvement in non-diabetic patients receiving the atypical neuroleptics: risperidone or...

Background: The precise quantification of negative symptoms is necessary to improve differential diagnosis and prognosis prediction in Schizophrenia. In chronic psychotic patients, the representation of verbal reports as word graphs provides automated sorting of schizophrenia, bipolar disorder and control groups based on the degree of speech connectedness. Here we aim to use machine learning to...

UNLABELLED The Glutamatergic system is the most important excitatory system of the human brain. Dysfunction of this system plays an important role in the pathogenesis of numerous psychiatric disorders, including schizophrenia. According to the glutamatergic hypothesis of schizophrenia augmentation of the antipsychotic treatment with glycine--a coagonist of NMDA receptor helps to achieve better ...

BACKGROUND Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia. METHODS An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion ...